Stocks · News reference
Polyrizon Completes Contracting With Fourth, Fifth Clinical Facilities Participating In Its Clinical Trial Of NASARIX Allergy Blocker
Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that it has completed
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 20, 2026, 1:31 PM
- Checked
- Aug 20, 2026, 1:31 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Polyrizon Receives Central IRB Approval To Begin First Human Clinical Trial For NASARIX, Nasal Spray Designed To Block Airborne Allergens
Read original at benzingaPolyrizon Publishes U.S. Patent Application No. US 2024/0358741 A1, titled "Mucoadhesive Polymers for Nasal Drug Delivery"
Read original at benzinga